Home News Broker's Calls

DBS maintains 'buy' on IHH following resignation of IHH Healthcare CEO Loh

The Edge Singapore
The Edge Singapore2/23/2023 09:47 AM GMT+08  • 1 min read
DBS maintains 'buy' on IHH following resignation of IHH Healthcare CEO Loh
Photo: Samuel Isaac Chua
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

DBS Group Research has maintained its “buy” call and $2.55 target price on IHH Healthcare, following the “surprised” resignation of CEO and managing director Kelvin Loh.

No further details were provided, other than Loh is leaving voluntarily.

“The resignation comes as a surprise and we believe it is untimely given it is too close to FY2022 results release,” says DBS in a Feb 23 note.

IHH Healthcare is due to report on Feb 28.

“While there are no further details available at this time, we note that there have been some recent changes in the Board of Directors, which saw two of IHH’s largest shareholders, Mitsui and Khazanah, change their respective representatives on the Board.

“We are not sure if these developments are related in any way,” adds DBS.

For now, DBS is not seeing “significant impact” on the healthcare group’s operations.

See also: RHB maintains 'buy' on Raffles Medical Group following strong revenue and China's reopening

“However, this could cause an overhang on the share price until a potential succession plan is known,” says DBS.

As at 9.46am, IHH Healthcare shares changed hands at $1.82, down 0.55%.

Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.